In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

 

COVID-19 framed much of the discussion around the pharma and medtech industries in 2021: vaccines were developed and deployed at record speeds and at-home COVID diagnostic tests became a staple in people’s day-to-day lives. And while the world grappled with lockdowns and restrictions to battle the pandemic, the life sciences sector thrived.

Biopharma raised record sums of venture capital financing in 2021, companies still managed successful IPOs and M&A action was continuous throughout the year – even if so-called megamergers were absent.

Certain companies and technologies became household names all around the globe because of their efforts to prevent and treat COVID-19, which opened the whole industry up to a new audience of connected, active, health-conscious patients.

Making predictions for the year ahead is always tricky, even more so with the Omicron variant raising new challenges for suppressing the spread of coronavirus and revealing the knowledge gaps we still have when it comes to understanding SARS-CoV-2. But the overall impression from biopharma and medtech insiders is a guardedly optimistic one. More deals and more financing opportunities are expected by the biotech crowd, as investors compete for the best assets in a cash-rich environment. And while European regulatory changes will present hurdles for medtech firms in 2022, there is room for growth – particularly in connected care and digital innovation. Elective care may well face another difficult year as COVID causes delays in hospitals. However, health care systems are not expected to close themselves off to non-urgent procedures to the same degree as was seen at the start of the pandemic.

We are not out of the woods yet with COVID-19 and “learning to live with the virus” is becoming more of a reality. Still, biopharma and medtech leaders have much to be positive about as we enter a new year.

Use the buttons above to navigate through Outlook 2022 for exclusive interviews and features on topics that reach across the life sciences. Outlook 2022 also includes industry league tables for Scrip 100, Medtech 100 and Generics Bulletin’s top 50.

Lucie Ellis
Executive Editor, In Vivo

Setting The Scene

Pharma Outlook 2022: What Next After A Year Of Innovation And Growth?

The biopharma industry broke records again in 2021 with the amount of money raised for drug development. After a year of rapid growth, what will 2022 bring for market dynamics and R&D catalysts in biopharma?

The Post-COVID Mantra For Medtechs: Prioritize, Optimize And Modernize

Medtech’s resilience and flexibility have been clear to see during the COVID-19 pandemic. In this forward-looking view for 2022, CEOs from some of the Top 50 global medtechs share their perspectives on the present and the future, from company and health care system standpoints.

UsernamePublicRestriction

Register